NCT-05488314

A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer

In this Phase 1/2 study, researchers are investigating the safety and effectiveness of combining two drugs, amivantamab and capmatinib, in treating advanced non-small cell lung cancer that cannot be surgically removed. The goal is to understand how well this combination therapy works and whether it causes any side effects.

Phase 1/2 study: A study that assesses the safety, effectiveness, and how well the treatment works

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05488314

Clinical Trial Site: Einstein

To see all available clinical trials click here.